Boehringer Ingelheim Venture Fund has participated in a $23.8m round for the antibody developer that was co-led by V-Bio Ventures and Advent France Biotechnology.
Agomab Therapeutics, a Belgium-based developer of tissue regeneration technology, has secured €21m ($23.8m) in series A funding from a consortium including pharmaceutical firm Boehringer Ingelheim.
The round was co-led by venture capital fund V-Bio Ventures and life sciences VC firm Advent France Biotechnology and included Omnes and Pontifax, while Boehringer Ingelheim invested through corporate venturing vehicle Boehringer Ingelheim Venture Fund (BIVF).
Founded in 2017, Agomab is developing antibodies for the regeneration of damaged tissue, with technology based on research by…
